Emergent BioSolutions Inc.
EBS
$11.60
$0.756.91%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -21.34% | -44.68% | -26.03% | -29.61% | 8.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.34% | -44.68% | -26.03% | -29.61% | 8.61% |
| Cost of Revenue | -23.61% | -74.95% | -35.59% | -42.78% | -27.23% |
| Gross Profit | -19.55% | 192.67% | -15.20% | 14.67% | 77.71% |
| SG&A Expenses | -57.06% | -43.08% | -37.85% | -32.10% | -17.31% |
| Depreciation & Amortization | 0.00% | -0.61% | 0.62% | 0.62% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.11% | -66.07% | -34.08% | -37.58% | -22.73% |
| Operating Income | 6.46% | 100.31% | 26.63% | 89.81% | 2,377.78% |
| Income Before Tax | -59.55% | 93.77% | 666.12% | 49.36% | 153.55% |
| Income Tax Expenses | -76.81% | -136.09% | 696.77% | 174.00% | 1,204.00% |
| Earnings from Continuing Operations | -55.40% | 95.76% | 655.56% | 36.77% | 143.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.40% | 95.76% | 655.56% | 36.77% | 143.58% |
| EBIT | 6.46% | 100.31% | 26.63% | 89.81% | 2,377.78% |
| EBITDA | 2.41% | 117.87% | 12.57% | 255.56% | 362.23% |
| EPS Basic | -55.49% | 95.89% | 625.06% | 39.45% | 142.52% |
| Normalized Basic EPS | -28.58% | 90.63% | 673.08% | 60.53% | 449.22% |
| EPS Diluted | -55.83% | 95.89% | 600.00% | 39.22% | 140.51% |
| Normalized Diluted EPS | -29.59% | 90.63% | 633.95% | 60.53% | 433.52% |
| Average Basic Shares Outstanding | 0.19% | 3.04% | 4.21% | 4.43% | 2.51% |
| Average Diluted Shares Outstanding | 1.62% | 3.04% | 9.77% | 4.43% | 7.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |